PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx*¡ªits digital pathology image management system¡ªfor use in primary diagnosis in clinical settings. Building on the initial 510(k) clearance for AISight Dx(Novo) in 2022, this latest milestone underscores the platform¡¯s continuous innovation and PathAI¡¯s commitment to delivering enhanced capabilities as the product evolves.

Microsoft has built an artificial intelligence-powered medical tool it claims is four times more successful than human doctors at diagnosing complex ailments, as the tech giant unveils research it believes could speed up treatment.

MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced a partnership with Negedia, an initiative born from Fondazione Telethon to expand access to DNBSEQ™-powered genomic sequencing and Stereo-seq spatial transcriptomics for precision medicine and biomedical research in Italy.

RetinalGenix Technologies Inc. OTCQB:RTGN (¡°RetinalGenix¡± or the ¡°Company¡±), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, has entered into an agreement with LabCorp, one of the nation¡¯s largest laboratory services organizations, to support the rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. This innovative program enables patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases.

Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, has received FDA clearance for the CN-6000™ Automated Blood Coagulation Analyzer. This clearance includes the reagent products used in five commonly performed hemostasis tests:

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing activities of its high-volume TrinScreen™ HIV rapid test, a cornerstone diagnostic product used in HIV screening programs. This regulatory approval marks a critical milestone in the Company¡¯s comprehensive transformation plan aimed at restoring financial performance and driving sustainable profitability.

6. Microfluidic Technology Microfluidic chip technology integrates basic operational units such as sample preparation, reaction, analysis, and detection, harnessing techniques from the fields of chemistry and bi..

Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter ¡°Fujirebio¡±) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter ¡°Plasma Services Group¡±). The transaction value has not been disclosed.

Roche¡¯s Largest Investment in China Breaks Ground with Initial Funding of RMB 3 Billion Recently, Roche Diagnostics (Suzhou) Co., Ltd. successfully obtained the construction permit for it..

Amazon has launched its first-ever at-home lab testing service in India. The new service, called Amazon Diagnostics, has been introduced in collaboration with Orange Health Labs, a diagnostics provider known for its convenience-focused model.

The European Commission decided to exclude Chinese companies from EU government purchases of medical devices exceeding €5 million. This measure follows the conclusions of the first investigation under the International Procurement Instrument (IPI), and allows no more than 50% of inputs from China for successful bids.

In a letter to customers on Wednesday, Bio-Rad Laboratories announced that it has decided against implementing a tariff surcharge that the company on May 21 said it was considering for at least some of its products. The surcharge came following the firm's disclosure of approximately $40 million in tariff-related revenue headwinds for 2025.

GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, today announced the initial closing of an $8.0 million Series C financing. The proceeds will be used to launch and commercialize GeneCentric¡¯s GenomicsNext™, the first integrated platform for comprehensive liquid biopsy testing that simultaneously provides thousands of gene expression measurements and high-fidelity DNA variant detection from circulating tumor DNA (ctDNA) in one sample.

Original from: business wire ¡¤ GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay development ¡¤ GENCURIX signs as inaugural par..